What is/are Acenocoumarol?
Acenocoumarol (marketed as Orencia) is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. It is a molecule capable of binding with more avidity to CD80 (B7-1) than to CD86 (B7-2). Abatacept is a selective co-stimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.
Research in the RECAVA network has discovered that two acquired factors (age and body mass index) and three genetic polymorphisms (genes VKORC1, CYP2C9 and CYP4F2) are useful to establish the correct dosage. Acenocoumarol is contraindicated during pregnancy.
This article uses material from the Wikipedia article Acenocoumarol , which is released under the Creative Commons Attribution-Share-Alike License 3.0.